UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive Outlook

In a report published Monday, BMO Capital Markets analyst Alex Arfaei upgraded the rating on Bristol-Myers Squibb BMY from Market Perform to Outperform, and raised the price target from $56.00 to $60.00. In the report, BMO Capital Markets noted, “We are upgrading BMY to Outperform from Market Perform based on our more positive outlook for the company's immuno-oncology (IO) pipeline and lower market expectations following the recent update on the Checkmate-012 trial...Now $60/share using DCF. Investors should buy BMY prior to ASCO and should not interpret potentially positive updates for MK-3475 as negative for BMY; this market will likely be large enough to accommodate multiple players.” Bristol-Myers Squibb closed on Friday at $50.33.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesAnalyst RatingsAlex ArfaeiBMO Capital Markets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!